Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05216510 · ClinicalTrials.gov registry record · Phase 1
Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens
A Phase 1 study, sponsored by Tonix Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT05216510 is a Phase 1 study that was terminated before completion, run by Tonix Pharmaceuticals. The registered enrollment target is 9 participants.
The verdict
NCT05216510, a Phase 1 study, was terminated before completion, sponsored by Tonix Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This dose finding, multi-cohort study is designed to evaluate the safety and efficacy of intradermally-injectedTNX-2100, synthesized SARS-CoV-2 peptide antigens and assess the presence and magnitude of DTH reactions.
Interventions
- BIOLOGICAL CANDIN
- BIOLOGICAL TNX-2110
- BIOLOGICAL TNX-2120
- BIOLOGICAL TNX-2130
- BIOLOGICAL Diluent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2022-01-07 |
| Est. Completion | 2022-09-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05216510
The ClinicalTrials.gov registry entry for NCT05216510 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tonix Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which CANDIN is the first listed.
NCT05216510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05216510 about?
NCT05216510 is a clinical study titled "Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens". This dose finding, multi-cohort study is designed to evaluate the safety and efficacy of intradermally-injectedTNX-2100, synthesized SARS-CoV-2 peptide antigens and assess the presence and magnitude of DTH reactions.
What is the current status of trial NCT05216510?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2022-01-07. Estimated completion is 2022-09-17.
What interventions are being tested in trial NCT05216510?
The interventions under investigation include: CANDIN (BIOLOGICAL), TNX-2110 (BIOLOGICAL), TNX-2120 (BIOLOGICAL), TNX-2130 (BIOLOGICAL), Diluent (BIOLOGICAL).
Who is sponsoring clinical trial NCT05216510?
This trial is sponsored by Tonix Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.